Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 65 Neoplasms 56 Prostatic Neoplasms 44 Lung Neoplasms 35 Colorectal Neoplasms 35 Carcinoma, Non-Small-Cell Lung 24 Pancreatic Neoplasms 21 Hematologic Neoplasms 19 Head and Neck Neoplasms 16 Neoplasm Metastasis 15 Urinary Bladder Neoplasms 12 Ovarian Neoplasms 11 Stomach Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 10 Motor Activity 10 Triple Negative Breast Neoplasms 9 Multiple Myeloma 9 Colonic Neoplasms 9 Melanoma 8 Glioma 8 Anxiety Disorders 8 Uterine Cervical Neoplasms 7 Hematopoietic and Lymphatic System Neoplasm 7 Glioblastoma 7 Gastrointestinal Neoplasms 7 Esophageal Neoplasms 7 Anatomic Stage I Breast Cancer AJCC v8 7 Smoking Cessation 6 Sarcoma 6 Rectal Neoplasms 6

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Neoadjuvant Therapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Muscle-Invasive Bladder Carcinoma × Standard of Care × Clear all

NCT04724928 2025-01-15

EFFORT-MIBC

University Hospital, Ghent

Phase 2 Recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡